Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Xspray Pharma AB ( (SE:XSPRAY) ) has issued an announcement.
Xspray Pharma AB has announced the publication of a disclosure document in connection with a rights issue to raise approximately SEK 130 million, offering preferential rights to existing shareholders. This move, registered with the Swedish Financial Supervisory Authority, aims to strengthen the company’s financial position and support its ongoing clinical developments, potentially impacting its market positioning in the oncology sector.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in developing improved versions of marketed protein kinase inhibitors (PKIs) using its patented HyNap™ technology. The company focuses on the oncology market, aiming to become a leader in enhanced PKIs for cancer treatment. Its lead drug candidate, Dasynoc®, is under FDA review and offers advantages such as bioequivalence at a lower dose and compatibility with proton pump inhibitors.
YTD Price Performance: 5.00%
Average Trading Volume: 39,069
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.59B
See more data about XSPRAY stock on TipRanks’ Stock Analysis page.